stocktitan.netAUG 271 min read$JHX

James Hardie (NYSE: JHX) exec sells shares after $11.23 options exercise

James Hardie (JHX) President Jonathan Skelly exercised 50,000 employee stock options at $11.23 per share and sold 65,000 shares at $30.45-$30.46, totaling $1.98M. The options were assumed during the AZEK Company acquisition. Skelly holds 287,721 options and 309,906 shares post-transaction.

Original reporting

stocktitan.net

Published Aug 27, 2026, 11:15 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 27, 2026, 12:21 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefFinancial news

Primary signal

$JHX

Neutral

medium confidence

Mentioned

$JHX

Relevance

5/10

AlphAI data visualization · based on stocktitan.net

Decision brief

The 30-second read

$JHXNeutralLow

Why it matters

The transaction provides fresh data on insider sentiment but is unlikely to move the stock significantly.

Market read

Primary insider filing; modest relevance for traders monitoring insider activity.

What to watch

Holding of 287,721 options suggests continued long‑term confidence.

Relevance 5/10Novelty 6/10Timing: 2026-08-25 (same‑day filing)

Background

James Hardie Industries plc (JHX) disclosed a Form 4 filing showing executive Jonathan Skelly's option exercise and share sale.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$JHXNeutralMedium confidence

Context

President Jonathan Skelly exercised 50,000 options at $11.23 and sold 65,000 shares at ~$30.45 on 2026-08-25, generating $1.98M cash.

Expected impact

Potential short-term downward pressure, likely limited to a few cents.

Evidence & confidence

Sale size is modest for a mid-cap; insider is a senior exec, but no 10b5-1 plan, suggesting discretionary action.

Market effects

Sector

None specific; reflects typical insider activity in building products sector.

Regional

US market only; no broader regional effect.

Global

Low

Counterpoint

What could challenge this read

Insider sale could be routine liquidity event rather than a negative signal.

Key entities

company
James Hardie Industries plc
Building products manufacturer listed on NYSE.
person
Jonathan Skelly
President of James Hardie North America.

Read at source ← All news

SEP 16

$JHXHighAI 8/10

James Hardie Lifts Cash Flow Goal; JHX Slides 5% as Earnings Forecasts Hold

James Hardie raised its fiscal 2027 free-cash-flow target to US$600M but kept sales and adjusted EBITDA forecasts unchanged. Shares fell 5.1% to A$37.37. The company expects to reach AZEK cost-synergy targets earlier. Investors await evidence of organic growth and demand validation.

ts2.tech2 min

SEP 16

$JHXMed

James Hardie upgrades FY27 cash flow guidance but not earnings, shares dip 5%

James Hardie (JHX) raised its FY27 free cash flow guidance by 20% to ~US$600M, but shares fell 5% as sales and earnings guidance remained unchanged. The company expects to achieve US$125M in cost synergies a year ahead of schedule. Management stated the guidance does not assume a housing recovery. FY26 free cash flow was US$425M, after deal and integration costs of ~US$207M.

marketindex.com.au2 min

SEP 15

$JHXMedAI 8/10

James Hardie Outlines Growth Strategy; Confirms Q2, FY27 Sales, Adj. EBITDA Outlook

James Hardie Industries (JHX) presented its growth strategy at an investor day, targeting 4-7% growth above market. The company expects $500M in revenue synergies and raised its fiscal 2027 free cash flow guidance. It also accelerated its $125M cost synergy target by one year. Shares were down 1% in pre-market trading.

rttnews.com2 min

SEP 2

$JHXHighAI 8/10

James Hardie to sell Fermacell to Holcim

Holcim agreed to acquire Fermacell, a gypsum fiberboard specialist, from James Hardie Industries. The deal follows Holcim's recent integration of Xella International AG. No financial terms were disclosed.

euwid-wood-products.com1 min

AUG 24

$JHXHighAI 9/10

Fitch revises James Hardie outlook on European divestiture

Fitch affirmed James Hardie's 'BBB' rating and revised its outlook to Stable from Negative after the company agreed to sell its European business to Holcim for $980M. The deal, expected to close in 2027, includes the sale of Fermacell and the closure of its European fiber cement business. Fitch expects James Hardie's EBITDA leverage to decrease to 2.5x by FYE 2027, supported by debt paydown and sale proceeds. The European operations contributed 11.5% of revenue and 7.2% of EBITDA in fiscal 2026.

investing.com3 min

AUG 21